Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aspira Women's Health Inc.

Get SEC filing alerts via email and in your feed for Aspira Women's Health Inc.

AWH AWHL

Aspira Women's Health Inc.

About Aspira Women's Health Inc.

Aspira Women’s Health Inc. develops and commercializes noninvasive, AI-powered diagnostic tests for gynecologic diseases, focusing on ovarian cancer and endometriosis. Its key products include the OvaSuite tests (Ova1, Overa, OvaWatch) and pipeline assays like OVAinform and ENDOinform. Serving physicians and healthcare providers primarily in the U.S., Aspira operates a CLIA-certified lab and leverages proprietary biomarker and algorithm technologies to improve early disease detection and patient risk assessment.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aspira Women's Health Inc.

1
1
Aspira Women's Health Inc. Aspira Women’s Health Reports $676,000 Net Income in Q1 2026, Revenue Declines 14%

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Aspira Women's Health Inc. Aspira Women’s Health Reports Modest Revenue Increase and Significant Cost Reductions for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Aspira Women's Health Inc. Aspira Women’s Health Reports Q3 2025 Revenue Growth Despite Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aspira Women's Health Inc. Aspira Women’s Health Reports Q2 2025 Financial Results with Revenue of $2.4 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aspira Women's Health Inc. Aspira Women’s Health Reports 6% Revenue Growth to $2.3 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aspira Women's Health Inc. Aspira Women's Health Reports $13.1 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Aspira Women's Health Inc. Aspira Women's Health Reports Mixed Q3 Results, Net Loss Improvement, and Strategic Focus on Product Development

Via official filing (AI summary) | over 1 year ago | 0 comments